VARDENAFIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H32N6O4S
Molecular Weight	488.603
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1=NC(C)=C2N1NC(=NC2=O)C3=C(OCC)C=CC(=C3)S(=O)(=O)N4CCN(CC)CC4

InChI

InChIKey=SECKRCOLJRRGGV-UHFFFAOYSA-N

InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)

HIDE SMILES / InChI

Molecular Formula	C23H32N6O4S
Molecular Weight	488.603
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00862
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021400s017lbl.pdf

Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 5A 31 Target ID: CHEMBL1827 Sources: http://www.drugbank.ca/drugs/DB00862	Inhibitor 8504		1.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erectile dysfunction 35 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021400s017lbl.pdf	Primary		Approved 8583	Levitra Approved Use LEVITRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. Launch Date 2003

C_max

Value	Dose	Co-administered	Analyte	Population
30.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27318021	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		VARDENAFIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
22.83 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27318021	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		VARDENAFIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.21 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27318021	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		VARDENAFIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
2.4 mg 12 times / day multiple, respiratory Highest studied dose Dose: 2.4 mg, 12 times / day Route: respiratory Route: multiple Dose: 2.4 mg, 12 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	healthy, 27.5 years (range: 24-31 years) Health Status: healthy Age Group: 27.5 years (range: 24-31 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	Sources: https://pubmed.ncbi.nlm.nih.gov/33325799
120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	Other AEs: Back pain, Myalgia... Other AEs: Back pain Myalgia Abnormal vision Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
2.4 mg single, respiratory Highest studied dose Dose: 2.4 mg Route: respiratory Route: single Dose: 2.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	healthy, adult Health Status: healthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	Sources: https://pubmed.ncbi.nlm.nih.gov/33325799
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	Disc. AE: Headache, Flushing... AEs leading to discontinuation/dose reduction: Headache (19 patients) Flushing (10 patients) Rhinitis (5 patients) Tachycardia (4 patients) Nausea (5 patients) Liver function test abnormal (4 patients) Dizziness (3 patients) Hypesthesia (3 patients) Abdominal pain (3 patients) Palpitations (3 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf

AEs

AE	Significance	Dose	Population
Abnormal vision		120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
Back pain		120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
Myalgia		120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
Flushing	10 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf
Headache	19 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf
Abdominal pain	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf
Dizziness	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf
Hypesthesia	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf
Palpitations	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf
Liver function test abnormal	4 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf
Tachycardia	4 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf
Nausea	5 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf
Rhinitis	5 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	substrate 1193 inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C8 1057 CYP2C19 2057	CYP3A5 446 CYP2C8 810 CYP2C19 1119 P-gp 2052 BCRP 697 MRP2 252

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	weak [Ki 126 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	weak [Ki 67.5 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	weak [Ki 73.2 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 1.4 uM]	M-1 6
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 20.6 uM]	M-4 4
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 45 uM]	M-1 6
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 45 uM]	M-1 6
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 9.8 uM]	M-1 6

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	major	yes (co-administration study) Comment: label: coadministration with ketoconazole (inhibitor) increased mean AUC and Cmax of vardenafil by 10-fold and 4-fold, respectively; coadministration with erythromycin (CYP3A4 substrate) increased mean AUC and Cmax of vardenafil, respectively; coadministration with indinavir (CYP3A4 inhibitor) increased mean AUC and Cmax of vardenafil by 16 fold and 7 fold, respectively; Ritonavir co-administered with vardenafil resulted in a 49-fold increase in vardenafil AUC and a 13 fold increase in vardenafil Cmax; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
CYP3A5 446	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/22775210/ Page: 7.0	yes
MRP2 252	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/22775210/ Page: 7.0	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/22775210/ Page: 7.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=17 Page: 17.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:46295	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:46295
eMolecules	30390394	https://www.emolecules.com/cgi-bin/more?vid=30390394
eMolecules	36366753	https://www.emolecules.com/cgi-bin/more?vid=36366753
eMolecules	36516854	https://www.emolecules.com/cgi-bin/more?vid=36516854
MolPort	MolPort-002-672-272	https://www.molport.com/shop/molecule-link/MolPort-002-672-272
ZINC	ZINC000018324776	http://zinc15.docking.org/substances/ZINC000018324776

PubMed

Title	Date	PubMed
Emerging oral drugs for erectile dysfunction.	2004-05	15155143
The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men.	2004-05	15082207
Erectile dysfunction: management update.	2004-04-27	15111479
[Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].	2004-04	15148932
Tadalafil and vardenafil.	2004-04	15124623
Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters.	2004-04	15115192
Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.	2004-04	15115191
Role of the cardiologist: clinical aspects of managing erectile dysfunction.	2004-04	15115189
Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction.	2004-04	15102574
Pills for erectile dysfunction: now there are three.	2004-04	15100064
Treatment of erectile dysfunction.	2004-04	15075013
Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction.	2004-03	15117088
Vardenafil--PDE5 inhibitor number 3.	2004-03	15117087
Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.	2004-03	15083994
Therapeutic options for patients returning to sexual activity.	2004-03	15083992
[Treatment of erectile dysfunction].	2004-02-29	15077482
New tools 2003.	2004-02-20	14971333
Cialis is here. The soft sell.	2004-02-02	14974376
Tadalafil (Cialis) and vardenafil (Levitra) recently approved drugs for erectile dysfunction.	2004-02	15054911
[Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy].	2004-02	14991124
Drug approval highlights for 2003.	2004-02	14872168
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.	2004-02	14871543
Vardenafil treatment for erectile dysfunction.	2004-01	14742800
Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.	2004-01	14734283
Spotlight on vardenafil in erectile dysfunction.	2004	14960129
FDA approves new drug for treatment of erectile dysfunction in men.	2003-12-12	14666896
Novel PDE5 inhibitors for the treatment of male erectile dysfunction.	2003-12-06	14656408
Oral drug treatment of erectile dysfunction.	2003-12	14695970
Pro-erectile effect of vardenafil: in vitro experiments in rabbits and in vivo comparison with sildenafil in rats.	2003-12	14644128
Vardenafil: a new approach to the treatment of erectile dysfunction.	2003-12	14622502
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.	2003-12	14622499
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.	2003-11-06	14609619
Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.	2003-11	14693300
New drugs and dosage forms.	2003-10-01	14531237
[Drug therapy of erectile dysfunction--the current status].	2003-10	14569380
Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.	2003-10	14551572
Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy.	2003-10	14501741
Vardenafil (levitra) for erectile dysfunction.	2003-09-29	14506469
Therapy of ED: PDE-5 Inhibitors.	2003-09-15	15146092
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.	2003-09-04	12955149
[Medication of the month. Vardenafil (Levitra)].	2003-09	14626653
Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups.	2003-09	12946758
Phosphodiesterase 5 inhibitors in male sexual dysfunction.	2003-09	12917517
US advertising campaign begins for alternative to sildenafil.	2003-08-30	12946961
Hypogonadism and erectile dysfunction: the role for testosterone therapy.	2003-08	12934045
Erectile dysfunction in the cardiac patient: how common and should we treat?	2003-08	12853773
[New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].	2003-06-26	12916343
[Conservative treatment of erectile dysfunction].	2003-06-01	12847815
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.	2003-06	12852189
Vardenafil: a review of its use in erectile dysfunction.	2003	14636086

Patents

Sample Use Guides

In Vivo Use Guide

For most patients, the starting dose is 10 mg, up to once daily. Increase to 20 mg or decrease to 5 mg based on efficacy/tolerability. A starting dose of 5 mg LEVITRA should be considered in patients ≥ 65 years of age. LEVITRA is taken orally, approximately 60 minutes before sexual activity. The maximum recommended dosing frequency is one tablet per day.

Route of Administration: Oral

In Vitro Use Guide

Treatment with vardenafil at concentrations of 50, 100, and 250 umol/L increased expression of PlGF in a dose-dependent manner in human umbilical vein endothelial cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:13 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:13 GMT 2025`
Record UNII	UCE6F4125H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VARDENAFIL

Official Name

English

VIVANZA

Preferred Name

English

VARDENAFIL [USAN]

Common Name

English

VARDENAFIL [EMA EPAR]

Common Name

English

VARDENAFIL [VANDF]

Common Name

English

VARDENAFIL [HSDB]

Common Name

English

vardenafil [INN]

Common Name

English

Vardenafil [WHO-DD]

Common Name

English

VARDENAFIL [MART.]

Common Name

English

1-((3-(3,4-DIHYDRO-5-METHYL-4-OXO-7-PROPYLIMIDAZO(5,1-F)-AS-TRIAZIN-2-YL)-4-ETHOXYPHENYL)SULFONYL)-4-ETHYLPIPERAZINE

Common Name

English

BAY-389456

Code

English

VARDENAFIL [MI]

Common Name

English

BAY38-9456

Code

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

LEVITRA (AUTHORIZED: ERECTILE DYSFUNCTIONS)